Ethiopia has taken a significant step in combating one of Africa’s deadliest diseases with the official launch of the R21/Matrix-M malaria vaccine in Turmi, located in the South Ethiopia Region. This achievement marks Ethiopia as the 23rd African country to introduce a malaria vaccine and the first to adopt an integrated approach combining vaccination with the widespread distribution of insecticide-treated bed nets (ITNs).
The initial phase involves administering over 186,000 doses of the vaccine to children most at risk of malaria, targeting 58 high-burden districts across the country. This rollout not only aims to reduce malaria-related deaths but also strengthens equitable access to health services and builds resilient primary health care systems in Ethiopia.
Malaria remains a leading cause of child mortality in Africa, claiming the lives of approximately 430,000 children under five each year. Ethiopia’s initiative advances prevention through a three-pronged strategy, blending vaccination with preventive tools and community awareness to combat the disease effectively.
By integrating the R21/Matrix-M vaccine with established malaria control measures, Ethiopia sets a new model for comprehensive malaria prevention, aiming to safeguard vulnerable populations and move closer to eliminating the disease as a public health threat.
